首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >Massive Pulmonary Embolism in a Patient Using Warfarin at Therapeutic Dose
【2h】

Massive Pulmonary Embolism in a Patient Using Warfarin at Therapeutic Dose

机译:使用华法林治疗剂量的患者发生大规模肺栓塞

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Warfarin sodium is commonly used for the prevention and treatment of thromboembolism. The efficacy of warfarin therapy depends on maintaining the International Normalised Ratio (INR) within the target range for the indication. A 56-year-old male presented to the emergency department with dyspnea and chest pain, together with pain and swelling in both legs. The patient had been taking warfarin at the therapeutic dose since having undergone an aortic valve replacement four years ago. His vital signs were an arterial pressure of 60/30 heart rate of 138 beats per minute, respiratory rate of 30 per minute and oxygen saturation of 60%. Computed tomography of the chest revealed thrombosis of the right pulmonary artery and its segmental branches. On investigating the aetiology of the venous thromboembolism, the level of Antithrombin III (AT III) activity was found to be at 37% (normal range, 80–120%).
机译:华法林钠通常用于预防和治疗血栓栓塞。华法林疗法的疗效取决于将国际标准化比率(INR)维持在适应症的目标范围内。一名56岁的男性因呼吸困难和胸痛以及双腿疼痛和浮肿而出现在急诊科。自四年前进行主动脉瓣置换以来,该患者一直在服用华法林。他的生命体征是动脉压为60/30,每分钟心跳138次,呼吸频率为每分钟30次,氧饱和度为60%。胸部计算机断层扫描显示右肺动脉及其节段血栓形成。在调查静脉血栓栓塞的病因时,发现抗凝血酶III(AT III)活性水平为37%(正常范围为80-120%)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号